BRD4 and acute myeloid leukemia: In leukemia, our prior research found that GNE‐987, a von Hippel‐Lindau‐based Proteolysis Targeting Chimera (PROTAC) targeting the critical SE reader Bromodomain containing 4 (BRD4), can inhibit the expression of a range of SE‐driven genes and hinder the survival of T‐ALL and acute myeloid leukemia (AML) cells.[20, 21, 22] In this study, to identify new key oncogenes in T‐ALL, we built profiles of SEs by analyzing ChIP‐seq data from clinical samples and cell lines.